This site is intended for healthcare professionals
News

The phase III GEM-3 trial of Vyjuvek meets primary endpoint in dystrophic epidermolysis bullosa.

Read time: 1 mins
Last updated:20th Dec 2021
Published:30th Nov 2021
New data from the phase III GEM-3 trial of Vyjuvek (beremagene geperpavec), from Krystal Biotech, for the treatment of patients with dystrophic epidermolysis bullosa has met its primary endpoint of complete wound healing at the six-month mark.

The pivotal study included 31 patients with dystrophic epidermolysis bullosa who had one wound treated weekly with a topical application of Vyjuvek while another was treated with placebo. The study's primary outcome measure was complete wound healing at six-month, while secondary goals included investigator-assessed complete wound healing at the three-month mark and mean change in pain severity.

According to top-line results, data showed that 67% of wounds treated with Vyjuvek achieved the primary endpoint, compared to 22% of wounds treated with placebo. At the same time, 71% of wounds treated with the gene therapy achieved the secondary endpoint of wound healing at the three-month limit, versus 20% of wounds treated with placebo. Results show that Vyjuvek was well tolerated, with only one mild drug-related adverse event reported. In addition, the immunogenicity profile of the gene therapy, that delivers two copies of the COL7A1 gene, was consistent with previous research and no meaningful changes in anti-HSV-1 or anti-COL7 antibodies were seen.

Condition: Epidermolysis Bullosa
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.